News

Agreement enables rapid, efficient and impactful expansion to the primary care physician audience. HLS will continue to focus primarily on specialists while Pfizer will focus primarily on primary...

Q2 2021 revenue of $14.9 million and Adjusted EBITDA of $6.6 million, up 19% and 36%, respectively, from Q2 2020 Generated strong Vascepa® prescription growth - amid persistent COVID-19...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, CEO, and Tim...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 2021 financial results on Thursday, August 5, 2021. The Company will hold a conference call that...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces voting results from its Annual Meeting...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it will be participating in Renmark...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it will be participating...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, CEO, and...

Q1 2021 revenue of $14.3 million, Adjusted EBITDA of $6.7 million and cash from operations of $7.2 million, up $0.4 million, $0.6 million and $1.8 million, respectively, from Q1 2020 Vascepa...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 2021 financial results on Thursday, May 6, 2021. The Company will hold a conference call that same...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, CEO, and...

HLS Therapeutics Inc. regrets the adoption of a new regulation, published yesterday in the Gazette officielle du Québec, which limits access to a support program for new patients suffering from...

Dorval, le 1er avril 2021. — HLS Therapeutics Inc. déplore l’adoption d’un nouveau règlement, publié hier dans la Gazette officielle du Québec, qui aura des conséquences sur l’accès...

CCS dyslipidemia management guidelines published in the Canadian Journal of Cardiology (CJC) on March 26, 2021 Strong recommendation for the use of icosapent ethyl for Primary Prevention (diabetes...

Fourth quarter revenue of $16.5 million, Adjusted EBITDA of $8.7 million and cash from operations of $5.8 million Produced strong Vascepa® prescription growth amid COVID-19 challenges: more than...

28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%,...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q4 and fiscal 2020 financial results by press release at 6:30 a.m. EST on Thursday, March 18, 2021....

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that it will participate in...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that it will be participating...

Private payer health plan coverage in Canada for Vascepa is expected to reach more than 80% by the end of February 2021, up from 50% in November 2020 Coverage effective for statin-treated patients...

Vascepa included in Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology1 Chinese Society of Cardiology updated Guidelines now include...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that it intends to redeem the...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that John L. Welborn, Jr.,...

Health Canada approves MyCare Psychiatry Lab Assays for use in diagnostic lab settings to measure blood levels in patients prescribed six of the most common antipsychotic drugs MyCare Insite...

Results presented in Late Breaker session at National Lipid Association Scientific Sessions 2020 Vascepa COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that in connection with its...

first once-monthly risperidone long-acting injectable used in the treatment of schizophrenia once-monthly dosing may help improve treatment compliance PERSERIS is a first-line treatment option for...

Results from Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at American Heart Association's Virtual Scientific Sessions 2020 VASCEPA®, compared with placebo, significantly...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, Chief...

Revenue of $13.1 million, Adjusted EBITDA of $4.5 million and cash from operations of $2.4 million Produced strong Vascepa prescription growth amid COVID-19 challenges: approximately 1,200...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 2020 financial results by press release at 6:30 a.m. Eastern Daylight Time on Thursday, November 5,...

In vitro data presented provides additional insight into potential mechanisms by which Vascepa reduces cardiovascular risk TORONTO, Oct. 22, 2020 /CNW/ - "The Vascepa story continues to unfold as...

HLS anticipates the portfolio will generate sustained and diversified revenues and cash flows Portfolio forecasted to generate an IRR in excess of 20% per year for at least ten years Compelling...

U.S. decision does not relate to Vascepa in Canada Vascepa was granted 8 years of data exclusivity by Health Canada upon approval Vascepa patent estate could potentially extend protection in...

Primary endpoint of slowed coronary plaque progression reported to have been met with VASCEPA Significant coronary plaque regression of low attenuation plaque (LAP) reported with VASCEPA provides...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, President...

Revenue of $12.6 million and Adjusted EBITDA of $4.8 million Increasing peak-year sales estimate for Vascepa to C$275-325 million Clozaril's Canadian patient count and sales in local currency...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 2020 financial results by press release at 6:30 a.m. Eastern Time on Thursday, August 6, 2020. The...

CADTH recommends Vascepa be reimbursed for patients with established cardiovascular disease under certain conditions. PMPRB notifies HLS that following PMPRB's review, Vascepa's introductory price...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces voting results from its Annual...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, President...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, confirms that its Annual Meeting of...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Greg Gubitz, Chief...

The MyCare Insite is a point-of-care (POC) device that uses just a single drop of blood to measure the most commonly used antipsychotic drugs in patients' blood The MyCare Psychiatry Clozapine...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that in collaboration with...

Revenue of $13.9 million, Adjusted EBITDA of $6.1 million and Cash from Operations of $5.3 million Launched Vascepa® in the Canadian market Vascepa added to Health Canada's Register of Innovative...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 2020 financial results by press release at 6:30 a.m. Eastern Time on Thursday, May 7, 2020. The...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, comments on the United States District...

Revenue of $54.2 million, Adjusted EBITDA of $31.6 million and Cash from Operations of $26.4 million Received approval from Health Canada for Vascepa® to reduce the risk of cardiovascular events...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, announces that it will release its...